Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
AXUMIN (FLUCICLOVINE F-18) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
AXUMIN
NDA
Get alerts
FLUCICLOVINE F-18 | N208054 | BLUE EARTH DIAGNOSTICS LTD
1 strength
8 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
8 unique patents by expiration date
Expiring < 1yr (3)
Active (5)
Today
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
Today
9387266
Nov. 28, 2026
10010632
Nov. 28, 2026
10124079
Dec. 30, 2035
10716868
Dec. 30, 2035
10933147
Dec. 30, 2035
10953112
Nov. 28, 2026
10967077
Dec. 30, 2035
11980674
Apr. 23, 2042
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 9-221mCi/ML
RLD
8 patents
0 exclusivities
▴
SOLUTION;INTRAVENOUS | Approved: May 27, 2016
Patents (8)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9387266
Nov 28, 2026
—
—
—
U-1879
METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
—
10010632
Nov 28, 2026
—
—
Yes
—
—
10124079
Dec 30, 2035
—
—
—
U-2450
POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
—
10716868
Dec 30, 2035
—
—
—
U-2450
POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
—
10933147
Dec 30, 2035
—
—
—
U-2450
POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
—
10953112
Nov 28, 2026
—
—
—
U-1879
METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
—
10967077
Dec 30, 2035
—
—
—
U-2450
POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
—
11980674
Apr 23, 2042
—
—
—
U-2450
POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
—